Head and Neck Squamous Cell Carcinoma Clinical Trial
Official title:
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Verified date | March 2024 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase II/III trial studies how well radiation therapy works with durvalumab or cetuximab in treating patients with head and neck cancer that has spread to a local and/or regional area of the body who cannot take cisplatin. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. It is not known if radiation therapy with durvalumab will work better than the usual therapy of radiation therapy with cetuximab in treating patients with head and neck cancer.
Status | Active, not recruiting |
Enrollment | 196 |
Est. completion date | September 21, 2024 |
Est. primary completion date | September 20, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - PRIOR TO STEP 1 REGISTRATION INCLUSION CRITERIA - Patients must have pathologically confirmed, previously untreated, unresected squamous cell carcinoma of the larynx, hypopharynx, oropharynx, oral cavity, or carcinoma of unknown head/neck primary prior to step 1 registration; submission of hematoxylin and eosin (H&E) stained slides and formalin-fixed and paraffin-embedded (FFPE) tissue block (or punch biopsy of FFPE block) to the biospecimen bank at University of California, San Francisco (UCSF) for central review for oropharyngeal and unknown primaries and for p16 analysis for all other non-oropharyngeal primaries is mandatory for all patients; investigators should check with their pathology department regarding release of biospecimens before approaching patients about participation in the trial; for oropharyngeal and unknown primaries, submission of H&E and p16 stained slides (with the required block for PD-L1) to the biospecimen bank at UCSF for central review is also required prior to step 2 registration - Note: fine needle aspirates (FNA) samples are not acceptable since they do not provide enough material for PD-L1 and p16 testing; however, if a cell block derived from the FNA is available, it is allowable if there are sufficient cells present in the block for PD-L1 testing; Dr. Jordan will determine this upon receipt; for sites submitting FNA cell blocks for ALL patients they must do so within 7-10 business days from registering the patient; sites must confirm with their cytology/pathology labs to make sure they can provide the required material as the bank must be able to retain these samples for the mandatory testing - Patients must have locoregionally advanced head and neck squamous cell carcinoma (HNSCC) - For p16-positive oropharyngeal/unknown primaries, American Joint Committee on Cancer [AJCC] 8th edition stage III and selected stage I-II based on smoking status in pack-years - For laryngeal, hypopharyngeal, and oral cavity primaries and p16-negative oropharyngeal/unknown primaries, AJCC 8th edition stage III-IVB - Based on the following minimum diagnostic workup within 60 days prior to step 1 registration: - General history and physical examination by a radiation oncologist or medical oncologist or ear, nose and throat (ENT) or head & neck surgeon - For larynx, hypopharynx, and base of tongue primaries, a laryngopharyngoscopy (mirror and/or fiberoptic and/or direct procedure) is required, unless the patient cannot tolerate or refuses - Imaging of the head and neck with a neck CT or magnetic resonance imaging (MRI) (with contrast, unless contraindicated) or PET/CT; note that the CT portion of the PET/CT must be of diagnostic quality, including contrast administration unless contraindicated. If the CT portion of the PET/CT study is low-dose (non-diagnostic), then an additional CT or MRI study with contrast (unless contraindicated) is required - Chest imaging: chest CT with and without contrast (unless contraindicated) or PET/CT - Patients must have a contraindication to cisplatin as defined in the following bullet points; sites must complete the online tool at comogram.org prior to step 1 registration to determine if the patient is eligible; the scores must be recorded on a case report form (CRF) - Age >= 70 with moderate to severe comorbidity or vulnerability to cisplatin, defined as having one or more of the following conditions within 30 days prior to step 1 registration: - Modified Charlson Comorbidity Index >= 1 - Adult Comorbidity Evaluation (ACE)-27 Index >= 1 - Generalized Competing Event Model for Cancer Risk (GCE) omega PFS score < 0.80 - Geriatric screening (G-8) score =< 14 - Cancer and Aging Research Group (CARG) toxicity score >= 30% - Cumulative Illness Rating scale for Geriatrics (CIRS-G) score >= 4 OR - Age < 70 with severe comorbidity or vulnerability to cisplatin, defined as having two or more of the following conditions within 30 days prior to step 1 registration - Modified Charlson Comorbidity Index >= 1 - ACE-27 Index >= 1 - GCE omega PFS-score < 0.80 - G-8 score =< 14 - CARG Toxicity score >= 30% - CIRS-G score >= 4 OR - Age >= 18 with an absolute or relative contraindication to cisplatin, defined as one or more of the following within 30 days prior to step 1 registration: - Creatinine clearance (CC) > 30 and < 60 cc/min; for this calculation, use the Cockcroft-Gault formula - Zubrod performance status 2 prior to step 1 registration - Pre-existing peripheral neuropathy grade >= 1 - History of hearing loss, defined as either: - Existing need of a hearing aid OR - >= 25 decibel shift over 2 contiguous frequencies on a pretreatment hearing test as clinically indicated - Absolute neutrophil count (ANC) >= 1,000 cells/mm^3 (within 14 days prior to step 1 registration) - Platelets >= 100,000 cells/mm^3 (within 14 days prior to step 1 registration) - Hemoglobin >= 9.0 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 9.0 g/dl is acceptable) (within 14 days prior to step 1 registration) - Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 times institutional upper limit of normal (within 14 days prior to step 1 registration) - Serum bilirubin =< 1.5 x institutional upper limit of normal (within 14 days prior to step 1 registration) - Measured creatinine clearance (CL) > 30 mL/min or calculated creatinine CL > 30 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance (within 14 days prior to step 1 registration) - For women of childbearing potential, a negative serum or urine pregnancy test within 14 days prior to step 1 registration; Note: women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause; the following age-specific requirements apply: - Women < 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy) - Women >= 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses > 1 year ago, had chemotherapy-induced menopause with last menses > 1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy) - The patient or a legally authorized representative must provide study-specific informed consent prior to step 1 registration - PRIOR TO STEP 2 REGISTRATION INCLUSION CRITERIA - For patients with oropharyngeal or unknown primaries: p16 determination by immunohistochemistry (defined as greater than 70% strong nuclear or nuclear and cytoplasmic staining of tumor cells), confirmed by central pathology review - Note: for patients with oral cavity, laryngeal, and hypopharyngeal primaries, analysis of p16 status prior to step 2 registration/randomization is not required (p16 status will be analyzed centrally post-hoc); step 2 registration for these patients can be completed after step 1 registration Exclusion Criteria: - PRIOR TO STEP 1 REGISTRATION EXCLUSION CRITERIA - Prior invasive malignancy within the past 3 years (except for non-melanomatous skin cancer, and early stage treated prostate cancer); synchronous head and neck primaries are ineligible - Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields - Note: Prior external beam radiotherapy is excluded, but iodine 131 is allowed - Prior immunotherapy - Prior systemic therapy, including cytotoxic chemotherapy, biologic/targeted therapy, or immune therapy for the study cancer - Major surgery within 28 days prior to step 1 registration - Proven evidence of distant metastases - If both of the following conditions are present, the patient is ineligible: - =< 10 pack-year smoking history - p16-positive carcinoma of the oropharynx or unknown primary that are T0-3, N0-1 (AJCC 8th Edition) - Note: in the event that a registered patient with =< 10 pack-years has a p16-positive result on central review with the tumor and nodal stage T0-3, N0-1 (AJCC 8th Edition), then the site will be notified that the patient is ineligible - Zubrod performance status >= 3 - Body weight =< 30 kg - Patients with oral cavity cancer are excluded from participation if the patient is medically operable and resection of the primary tumor is considered technically feasible by an oral or head and neck cancers surgical subspecialist;(please consult the surgical oncology co-principal investigator [PI], Steven Chang, Doctor of Medicine [MD], if clarification is needed on an individual case) - Sodium < 130 mmol/L or > 155 mmol/L (within 14 days of step 1 registration, unless corrected prior to step 1 registration) - Potassium < 3.5 mmol/L or > 6 mmol/L (within 14 days of step 1 registration, unless corrected prior to step 1 registration) - Fasting glucose < 40 mg/dl or > 400 mg/dl (within 14 days of step 1 registration, unless corrected prior to step 1 registration) - Serum calcium (ionized or adjusted for albumin) < 7 mg/dl or > 12.5 mg/dl (within 14 days of step 1 registration, unless corrected prior to step 1 registration) - Magnesium < 0.9 mg/dl or > 3 mg/dl (within 14 days of step 1 registration, unless corrected prior to step 1 registration) - Unstable angina and/or congestive heart failure requiring hospitalization within 3 months prior to step 1 registration - Transmural myocardial infarction within 3 months prior to step 1 registration - Respiratory illness requiring hospitalization at the time of step 1 registration - Note: if the respiratory illness is resolved and the patient meets the eligibility status above, then the patient can be considered for the trial - Idiopathic pulmonary fibrosis or other severe interstitial lung disease that requires oxygen therapy or is thought to require oxygen therapy within 1 year prior to step 1 registration - History of (non-infectious) pneumonitis that required steroids or current pneumonitis - Clinically apparent jaundice and/or known coagulation defects - Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis], Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.) - The following are exceptions to this criterion: - Patients with vitiligo or alopecia; - Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement; - Any chronic skin condition that does not require systemic therapy; - Patients without active disease in the last 5 years may be included but only after consultation with the medical oncology study chair; - Patients with celiac disease controlled by diet alone - History of active primary immunodeficiency including, but not limited to acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; Note: human immunodeficiency virus (HIV) testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is necessary because the treatment involved in this protocol may be immunosuppressive; patients with known HIV, CD4 counts >= 200/uL, and undetectable viral loads who are stable on an antiretroviral regimen may be included - Current or prior use of immunosuppressive medication within 14 days before step 1 registration, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid - Receipt of live attenuated vaccination within 30 days prior to step 1 registration - Medical or psychiatric illness which would compromise the patient's ability to tolerate treatment or limit compliance with study requirements - Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception during treatment and for 6 months after the last dose of cetuximab or MEDI14736 (durvalumab); this exclusion is necessary because the treatment involved in this study may be significantly teratogenic; women who are breastfeeding are also excluded - Prior allergic reaction or hypersensitivity to cetuximab or MEDI4736 (durvalumab) or any of study drug excipients - History of allogenic organ transplantation - Uncontrolled hypertension - Uncontrolled cardiac arrhythmia - Uncontrolled serious chronic gastrointestinal condition associated with diarrhea - Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis [TB] testing in line with local practice), hepatitis B (known positive hepatitis B virus [HBV] surface antigen [HBsAg] result), hepatitis C; patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible; patients positive for hepatitis C (hepatitis C virus [HCV]) antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA) |
Country | Name | City | State |
---|---|---|---|
Canada | London Regional Cancer Program | London | Ontario |
Canada | The Research Institute of the McGill University Health Centre (MUHC) | Montreal | Quebec |
Canada | Allan Blair Cancer Centre | Regina | Saskatchewan |
Canada | University Health Network-Princess Margaret Hospital | Toronto | Ontario |
United States | Jefferson Abington Hospital | Abington | Pennsylvania |
United States | Atrium Health Stanly/LCI-Albemarle | Albemarle | North Carolina |
United States | New Mexico Oncology Hematology Consultants | Albuquerque | New Mexico |
United States | University of New Mexico Cancer Center | Albuquerque | New Mexico |
United States | Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor | Michigan |
United States | University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan |
United States | Langlade Hospital and Cancer Center | Antigo | Wisconsin |
United States | Kaiser Permanente-Deer Valley Medical Center | Antioch | California |
United States | Emory University Hospital Midtown | Atlanta | Georgia |
United States | Emory University Hospital/Winship Cancer Institute | Atlanta | Georgia |
United States | Grady Health System | Atlanta | Georgia |
United States | Sutter Cancer Centers Radiation Oncology Services-Auburn | Auburn | California |
United States | Augusta University Medical Center | Augusta | Georgia |
United States | UCHealth University of Colorado Hospital | Aurora | Colorado |
United States | Greater Baltimore Medical Center | Baltimore | Maryland |
United States | Memorial Sloan Kettering Basking Ridge | Basking Ridge | New Jersey |
United States | McLaren Cancer Institute-Bay City | Bay City | Michigan |
United States | Sanford Joe Lueken Cancer Center | Bemidji | Minnesota |
United States | Alta Bates Summit Medical Center-Herrick Campus | Berkeley | California |
United States | Billings Clinic Cancer Center | Billings | Montana |
United States | University of Alabama at Birmingham Cancer Center | Birmingham | Alabama |
United States | Boston Medical Center | Boston | Massachusetts |
United States | Trinity Health Medical Center - Brighton | Brighton | Michigan |
United States | James J Peters VA Medical Center | Bronx | New York |
United States | Montefiore Medical Center - Moses Campus | Bronx | New York |
United States | Crozer-Keystone Regional Cancer Center at Broomall | Broomall | Pennsylvania |
United States | Henry Ford Cancer Institute-Downriver | Brownstown | Michigan |
United States | Roswell Park Cancer Institute | Buffalo | New York |
United States | Lahey Hospital and Medical Center | Burlington | Massachusetts |
United States | Fairview Ridges Hospital | Burnsville | Minnesota |
United States | Saint Alphonsus Cancer Care Center-Caldwell | Caldwell | Idaho |
United States | Aultman Health Foundation | Canton | Ohio |
United States | Cleveland Clinic Mercy Hospital | Canton | Ohio |
United States | Trinity Health Medical Center - Canton | Canton | Michigan |
United States | Saint Francis Medical Center | Cape Girardeau | Missouri |
United States | IU Health North Hospital | Carmel | Indiana |
United States | Christiana Care Health System-Concord Health Center | Chadds Ford | Pennsylvania |
United States | UNC Lineberger Comprehensive Cancer Center | Chapel Hill | North Carolina |
United States | Geauga Hospital | Chardon | Ohio |
United States | Medical University of South Carolina | Charleston | South Carolina |
United States | Atrium Health Pineville/LCI-Pineville | Charlotte | North Carolina |
United States | Carolinas Medical Center/Levine Cancer Institute | Charlotte | North Carolina |
United States | University of Virginia Cancer Center | Charlottesville | Virginia |
United States | Chelsea Hospital | Chelsea | Michigan |
United States | John H Stroger Jr Hospital of Cook County | Chicago | Illinois |
United States | Northwestern University | Chicago | Illinois |
United States | Rush University Medical Center | Chicago | Illinois |
United States | University of Illinois | Chicago | Illinois |
United States | University of Cincinnati Cancer Center-UC Medical Center | Cincinnati | Ohio |
United States | McLaren Cancer Institute-Clarkston | Clarkston | Michigan |
United States | Case Western Reserve University | Cleveland | Ohio |
United States | Cleveland Clinic Foundation | Cleveland | Ohio |
United States | MetroHealth Medical Center | Cleveland | Ohio |
United States | Henry Ford Macomb Hospital-Clinton Township | Clinton Township | Michigan |
United States | Mercy Cancer Center-West Lakes | Clive | Iowa |
United States | Memorial Hospital North | Colorado Springs | Colorado |
United States | Penrose-Saint Francis Healthcare | Colorado Springs | Colorado |
United States | UCHealth Memorial Hospital Central | Colorado Springs | Colorado |
United States | Ohio State University Comprehensive Cancer Center | Columbus | Ohio |
United States | Memorial Sloan Kettering Commack | Commack | New York |
United States | Atrium Health Cabarrus/LCI-Concord | Concord | North Carolina |
United States | UM Sylvester Comprehensive Cancer Center at Coral Gables | Coral Gables | Florida |
United States | Good Samaritan Hospital | Corvallis | Oregon |
United States | Siteman Cancer Center at West County Hospital | Creve Coeur | Missouri |
United States | Geisinger Medical Center | Danville | Pennsylvania |
United States | Decatur Memorial Hospital | Decatur | Illinois |
United States | UM Sylvester Comprehensive Cancer Center at Deerfield Beach | Deerfield Beach | Florida |
United States | Iowa Methodist Medical Center | Des Moines | Iowa |
United States | Mercy Medical Center - Des Moines | Des Moines | Iowa |
United States | Henry Ford Hospital | Detroit | Michigan |
United States | Wayne State University/Karmanos Cancer Institute | Detroit | Michigan |
United States | City of Hope Comprehensive Cancer Center | Duarte | California |
United States | Kaiser Permanente Dublin | Dublin | California |
United States | Miller-Dwan Hospital | Duluth | Minnesota |
United States | Fairview Southdale Hospital | Edina | Minnesota |
United States | Crossroads Cancer Center | Effingham | Illinois |
United States | Sanford Roger Maris Cancer Center | Fargo | North Dakota |
United States | Weisberg Cancer Treatment Center | Farmington Hills | Michigan |
United States | McLaren Cancer Institute-Flint | Flint | Michigan |
United States | Singh and Arora Hematology Oncology PC | Flint | Michigan |
United States | Poudre Valley Hospital | Fort Collins | Colorado |
United States | Parkview Hospital Randallia | Fort Wayne | Indiana |
United States | Parkview Regional Medical Center | Fort Wayne | Indiana |
United States | Beebe South Coastal Health Campus | Frankford | Delaware |
United States | Kaiser Permanente-Fremont | Fremont | California |
United States | Fresno Cancer Center | Fresno | California |
United States | Kaiser Permanente-Fresno | Fresno | California |
United States | Unity Hospital | Fridley | Minnesota |
United States | Western Illinois Cancer Treatment Center | Galesburg | Illinois |
United States | Banner MD Anderson Cancer Center | Gilbert | Arizona |
United States | CTCA at Western Regional Medical Center | Goodyear | Arizona |
United States | Nebraska Cancer Specialists/Oncology Hematology West PC | Grand Island | Nebraska |
United States | Aurora BayCare Medical Center | Green Bay | Wisconsin |
United States | Saint Vincent Hospital Cancer Center at Saint Mary's | Green Bay | Wisconsin |
United States | Saint Vincent Hospital Cancer Center Green Bay | Green Bay | Wisconsin |
United States | Gibbs Cancer Center-Pelham | Greer | South Carolina |
United States | Hackensack University Medical Center | Hackensack | New Jersey |
United States | Smilow Cancer Hospital-Hamden Care Center | Hamden | Connecticut |
United States | Memorial Sloan Kettering Westchester | Harrison | New York |
United States | Margaret R Pardee Memorial Hospital | Hendersonville | North Carolina |
United States | Penn State Milton S Hershey Medical Center | Hershey | Pennsylvania |
United States | Hawaii Cancer Care Inc - Waterfront Plaza | Honolulu | Hawaii |
United States | Queen's Medical Center | Honolulu | Hawaii |
United States | The Cancer Center of Hawaii-Liliha | Honolulu | Hawaii |
United States | M D Anderson Cancer Center | Houston | Texas |
United States | Community Cancer Center East | Indianapolis | Indiana |
United States | Community Cancer Center North | Indianapolis | Indiana |
United States | Community Cancer Center South | Indianapolis | Indiana |
United States | Indiana University/Melvin and Bren Simon Cancer Center | Indianapolis | Indiana |
United States | Sidney and Lois Eskenazi Hospital | Indianapolis | Indiana |
United States | Allegiance Health | Jackson | Michigan |
United States | Baptist MD Anderson Cancer Center | Jacksonville | Florida |
United States | University of Wisconsin Carbone Cancer Center - Johnson Creek | Johnson Creek | Wisconsin |
United States | Kalispell Regional Medical Center | Kalispell | Montana |
United States | University of Kansas Cancer Center | Kansas City | Kansas |
United States | Aurora Cancer Care-Kenosha South | Kenosha | Wisconsin |
United States | Gundersen Lutheran Medical Center | La Crosse | Wisconsin |
United States | UC San Diego Moores Cancer Center | La Jolla | California |
United States | Karmanos Cancer Institute at McLaren Greater Lansing | Lansing | Michigan |
United States | Mid-Michigan Physicians-Lansing | Lansing | Michigan |
United States | University of Michigan Health - Sparrow Lansing | Lansing | Michigan |
United States | McLaren Cancer Institute-Lapeer Region | Lapeer | Michigan |
United States | Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Lebanon | New Hampshire |
United States | Geisinger Medical Oncology-Lewisburg | Lewisburg | Pennsylvania |
United States | Lewistown Hospital | Lewistown | Pennsylvania |
United States | University of Kentucky/Markey Cancer Center | Lexington | Kentucky |
United States | Cedars Sinai Medical Center | Los Angeles | California |
United States | Norton Brownsboro Hospital and Medical Campus | Louisville | Kentucky |
United States | Norton Hospital Pavilion and Medical Campus | Louisville | Kentucky |
United States | The James Graham Brown Cancer Center at University of Louisville | Louisville | Kentucky |
United States | Banner McKee Medical Center | Loveland | Colorado |
United States | University of Wisconsin Carbone Cancer Center - University Hospital | Madison | Wisconsin |
United States | Cleveland Clinic Cancer Center Mansfield | Mansfield | Ohio |
United States | Aurora Bay Area Medical Group-Marinette | Marinette | Wisconsin |
United States | Froedtert Menomonee Falls Hospital | Menomonee Falls | Wisconsin |
United States | UH Seidman Cancer Center at Lake Health Mentor Campus | Mentor | Ohio |
United States | East Jefferson General Hospital | Metairie | Louisiana |
United States | University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami | Florida |
United States | Memorial Sloan Kettering Monmouth | Middletown | New Jersey |
United States | Aurora Saint Luke's Medical Center | Milwaukee | Wisconsin |
United States | Medical College of Wisconsin | Milwaukee | Wisconsin |
United States | Zablocki Veterans Administration Medical Center | Milwaukee | Wisconsin |
United States | Hennepin County Medical Center | Minneapolis | Minnesota |
United States | University of South Alabama Mitchell Cancer Institute | Mobile | Alabama |
United States | Kaiser Permanente-Modesto | Modesto | California |
United States | Atrium Health Union/LCI-Union | Monroe | North Carolina |
United States | Forbes Hospital | Monroeville | Pennsylvania |
United States | Memorial Sloan Kettering Bergen | Montvale | New Jersey |
United States | West Virginia University Healthcare | Morgantown | West Virginia |
United States | McLaren Cancer Institute-Macomb | Mount Clemens | Michigan |
United States | ProHealth D N Greenwald Center | Mukwonago | Wisconsin |
United States | Saint Alphonsus Cancer Care Center-Nampa | Nampa | Idaho |
United States | Yale University | New Haven | Connecticut |
United States | Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York | New York |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
United States | NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center | New York | New York |
United States | Helen F Graham Cancer Center | Newark | Delaware |
United States | Sentara Norfolk General Hospital | Norfolk | Virginia |
United States | Kaiser Permanente Oakland-Broadway | Oakland | California |
United States | Kaiser Permanente-Oakland | Oakland | California |
United States | ProHealth Oconomowoc Memorial Hospital | Oconomowoc | Wisconsin |
United States | University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma |
United States | University of Kansas Cancer Center-Overland Park | Overland Park | Kansas |
United States | Stanford Cancer Institute Palo Alto | Palo Alto | California |
United States | VA Palo Alto Health Care System | Palo Alto | California |
United States | Methodist Medical Center of Illinois | Peoria | Illinois |
United States | OSF Saint Francis Medical Center | Peoria | Illinois |
United States | McLaren Cancer Institute-Northern Michigan | Petoskey | Michigan |
United States | Fox Chase Cancer Center | Philadelphia | Pennsylvania |
United States | Temple University Hospital | Philadelphia | Pennsylvania |
United States | Allegheny General Hospital | Pittsburgh | Pennsylvania |
United States | UPMC-Shadyside Hospital | Pittsburgh | Pennsylvania |
United States | McLaren-Port Huron | Port Huron | Michigan |
United States | Kaiser Permanente Northwest | Portland | Oregon |
United States | Providence Portland Medical Center | Portland | Oregon |
United States | Providence Saint Vincent Medical Center | Portland | Oregon |
United States | Kaiser Permanente-Rancho Cordova Cancer Center | Rancho Cordova | California |
United States | Beebe Health Campus | Rehoboth Beach | Delaware |
United States | Kaiser Permanente-Richmond | Richmond | California |
United States | VCU Massey Cancer Center at Stony Point | Richmond | Virginia |
United States | Virginia Commonwealth University/Massey Cancer Center | Richmond | Virginia |
United States | Mayo Clinic in Rochester | Rochester | Minnesota |
United States | University of Rochester | Rochester | New York |
United States | Rock Hill Radiation Therapy Center | Rock Hill | South Carolina |
United States | Rohnert Park Cancer Center | Rohnert Park | California |
United States | Kaiser Permanente-Roseville | Roseville | California |
United States | Sutter Cancer Centers Radiation Oncology Services-Roseville | Roseville | California |
United States | The Permanente Medical Group-Roseville Radiation Oncology | Roseville | California |
United States | Kaiser Permanente Downtown Commons | Sacramento | California |
United States | Kaiser Permanente-South Sacramento | Sacramento | California |
United States | South Sacramento Cancer Center | Sacramento | California |
United States | Sutter Medical Center Sacramento | Sacramento | California |
United States | University of California Davis Comprehensive Cancer Center | Sacramento | California |
United States | Ascension Saint Mary's Hospital | Saginaw | Michigan |
United States | Coborn Cancer Center at Saint Cloud Hospital | Saint Cloud | Minnesota |
United States | Dartmouth Cancer Center - North | Saint Johnsbury | Vermont |
United States | Mercy Hospital Saint Louis | Saint Louis | Missouri |
United States | Washington University School of Medicine | Saint Louis | Missouri |
United States | Regions Hospital | Saint Paul | Minnesota |
United States | Siteman Cancer Center at Saint Peters Hospital | Saint Peters | Missouri |
United States | Salina Regional Health Center | Salina | Kansas |
United States | Kaiser Permanente-San Francisco | San Francisco | California |
United States | UCSF Medical Center-Mission Bay | San Francisco | California |
United States | UCSF Medical Center-Mount Zion | San Francisco | California |
United States | Kaiser Permanente-Santa Teresa-San Jose | San Jose | California |
United States | Kaiser Permanente San Leandro | San Leandro | California |
United States | Kaiser San Rafael-Gallinas | San Rafael | California |
United States | North Coast Cancer Care | Sandusky | Ohio |
United States | Kaiser Permanente Medical Center - Santa Clara | Santa Clara | California |
United States | Kaiser Permanente-Santa Rosa | Santa Rosa | California |
United States | Guthrie Medical Group PC-Robert Packer Hospital | Sayre | Pennsylvania |
United States | University of Washington Medical Center - Montlake | Seattle | Washington |
United States | Vince Lombardi Cancer Clinic-Sheboygan | Sheboygan | Wisconsin |
United States | Avera Cancer Institute | Sioux Falls | South Dakota |
United States | Sanford USD Medical Center - Sioux Falls | Sioux Falls | South Dakota |
United States | City of Hope South Pasadena | South Pasadena | California |
United States | Kaiser Permanente Cancer Treatment Center | South San Francisco | California |
United States | Kaiser Permanente-South San Francisco | South San Francisco | California |
United States | Spartanburg Medical Center | Spartanburg | South Carolina |
United States | Memorial Medical Center | Springfield | Illinois |
United States | Kaiser Permanente-Stockton | Stockton | California |
United States | Stony Brook University Medical Center | Stony Brook | New York |
United States | Aurora Medical Center in Summit | Summit | Wisconsin |
United States | ProMedica Flower Hospital | Sylvania | Ohio |
United States | State University of New York Upstate Medical University | Syracuse | New York |
United States | Moffitt Cancer Center | Tampa | Florida |
United States | Torrance Memorial Medical Center | Torrance | California |
United States | Torrance Memorial Physician Network - Cancer Care | Torrance | California |
United States | Gene Upshaw Memorial Tahoe Forest Cancer Center | Truckee | California |
United States | Smilow Cancer Hospital Care Center-Trumbull | Trumbull | Connecticut |
United States | Banner University Medical Center - Tucson | Tucson | Arizona |
United States | University of Arizona Cancer Center-North Campus | Tucson | Arizona |
United States | Memorial Sloan Kettering Nassau | Uniondale | New York |
United States | Carle Cancer Center | Urbana | Illinois |
United States | Kaiser Permanente Medical Center-Vacaville | Vacaville | California |
United States | Kaiser Permanente-Vallejo | Vallejo | California |
United States | Kaiser Permanente-Walnut Creek | Walnut Creek | California |
United States | Smilow Cancer Hospital Care Center - Waterford | Waterford | Connecticut |
United States | UW Cancer Center at ProHealth Care | Waukesha | Wisconsin |
United States | Aspirus Regional Cancer Center | Wausau | Wisconsin |
United States | Aurora West Allis Medical Center | West Allis | Wisconsin |
United States | Froedtert West Bend Hospital/Kraemer Cancer Center | West Bend | Wisconsin |
United States | Henry Ford West Bloomfield Hospital | West Bloomfield | Michigan |
United States | University of Cincinnati Cancer Center-West Chester | West Chester | Ohio |
United States | Reading Hospital | West Reading | Pennsylvania |
United States | UHHS-Westlake Medical Center | Westlake | Ohio |
United States | University of Kansas Hospital-Westwood Cancer Center | Westwood | Kansas |
United States | Wexford Health and Wellness Pavilion | Wexford | Pennsylvania |
United States | Ascension Via Christi Hospitals Wichita | Wichita | Kansas |
United States | Geisinger Wyoming Valley/Henry Cancer Center | Wilkes-Barre | Pennsylvania |
United States | Asplundh Cancer Pavilion | Willow Grove | Pennsylvania |
United States | Cleveland Clinic Wooster Family Health and Surgery Center | Wooster | Ohio |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) | Canadian Cancer Trials Group, NRG Oncology |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Secondary Biomarker Analysis | Will perform multiparametric flow cytometry on peripheral mononuclear cells (PBMC) from patient-derived blood samples to quantify changes in immune cell frequency and activation status before, during and after radiation combined with cetuximab or radiation combined with durvalumab. To assess the statistical significance of pre- to post-treatment changes in levels of immunoglobulin (Ig)Gs as well as other markers, normalized signal intensities (log2) will be tested using a paired t test within an arm and two sample t test between the two arms. If the distribution assumption is violated for the t tests, nonparametric tests, such as the Wilcoxon signed-rank test will be considered. Lastly, the association between PFS and OS and post-treatment changes in frequency and activation state of T-cells, clonality and diversity of T cell receptor (TCR), and IgG levels will be evaluated using a two-sided Wald test at 0.05 level on the basis of Cox models. | Baseline up to 4 months after RT | |
Other | Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE) | PRO-CTCAE is not intended for expedited reporting, real time review or safety reporting. PRO-CTCAE data are exploratory and not currently intended for use in data safety monitoring or adverse event stopping rules. | Up to 3 years | |
Other | QOL Endpoints Using Other Items in EORTC QLQ/HN35, EQ5D and MDADI Subscales | The mean change from baseline at each time point will be summarized using mean and standard deviations for each arm. Mean change from baseline will be compared between the arms using a two sample t test. If data normality assumptions are not met, the Wilcoxon rank sum test will be used to test the hypothesis. Mean change from baseline will be tested using an omnibus F test followed by individual comparisons of change scores at different time points within each treatment group. The same analysis will be conducted for between group comparisons at each time point. | Up to 12-24 months from end of RT | |
Primary | (Lead-in) Number of Participants With Dose-limiting Toxicity (DLT) | DLTs were collected to verify the safety of durvalumab with RT in this population. Safety was determined if = 2 of 8 participants in the cohort had any DLT, in which case the study would proceed to phase II with that dose schedule (DS). The probability for the DS to be deemed too toxic, given a true toxicity rate = 45%, is at least 78%. With a true toxicity rate = 20%, the probability for the DS do be deemed safe is 80%. The full DLT definition does not fit here, but includes all grade 5 AEs, grade 3 or 4 AEs definitely or probably related to durvalumab (DPRD) except for specified AEs and situations, and incomplete or > 2-week delay completing RT due to immune toxicity DPRD. AEs were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, which grade severity from 1=mild to 5=death. Two alternate DSs with a delayed 2nd dose (to reduce/avoid doses concurrent with RT) would be tried if the initial DS was too toxic. | From start of durvalumab to 4 weeks after radiation therapy, approximately 13 weeks. Weekly during RT, at RT end, prior to adjuvant durvalumab, one month after end of RT. | |
Primary | Progression-free Survival (Percentage of Participants Alive Without Progression) | Progression (failure) is defined as local, regional, or distant disease progression, or death from any cause. Progression was assessed by imaging, clinical assessment, or biopsy.
Failure time is defined as time from randomization to failure or last follow-up (censored). Failure rates are estimated using the Kaplan-Meier method. The protocol specifies that the distributions of failure times be compared between the arms, which is reported in the statistical analysis results. Two-year estimates are provided. Analysis was planned to occur after 69 failure events had been reported. |
From randomization to last follow-up: weekly during RT, after end of RT: every 4 months for 1 year, every 6 months for 2 years, then annually. Additionally, every 4 weeks during adjuvant durvalumab. Maximum follow-up at time of analysis was 4.2 years. | |
Primary | Overall Survival (Percentage of Participants Alive) | Overall survival (OS) time is defined as time from randomization to the date of death from any cause or last known follow-up (censored). Overall survival rates are estimated by the Kaplan-Meier method. The protocol specifies that the distributions of failure times be compared between the arms, which is reported in the statistical analysis results. Two-year estimates are provided. | From randomization to last follow-up: weekly during RT, after end of RT: every 4 months for 1 year, every 6 months for 2 years, then annually. Additionally, every 4 weeks during adjuvant durvalumab. Maximum follow-up at time of analysis was 4.2 years. | |
Secondary | Locoregional Failure (Percentage of Participants With Locoregional Failure) | Locoregional progression is defined as local or regional progression or recurrence, death due to study cancer or unknown causes without documented progression. Progression was assessed by imaging, clinical assessment, or biopsy. Failure time is defined as time from randomization to failure, distant metastasis (competing risk), deaths from other causes (competing risk), or last follow-up (censored). Failure rates are estimated using the cumulative incidence method. The protocol specifies that the distributions of failure times be compared between the arms, which is reported in the statistical analysis results. Two-year estimates are provided. | From randomization to last follow-up: weekly during RT, after end of RT: every 4 months for 1 year, every 6 months for 2 years, then annually. Additionally, every 4 weeks during adjuvant durvalumab. Maximum follow-up at time of analysis was 4.2 years. | |
Secondary | Distant Metastasis (Percentage of Participants With Distant Metastasis) | Failure is defined as the occurrence of distant metastasis. Failure time is defined as time from randomization to first occurrence of distant metastasis, local or regional progression or recurrence (competing risk), death (competing risk), or last follow-up (censored). Failure rates are estimated using the cumulative incidence method. The protocol specifies that the distributions of failure times be compared between the arms, which is reported in the statistical analysis results. Two-year estimates are provided. | From randomization to last follow-up: weekly during RT, after end of RT: every 4 months for 1 year, every 6 months for 2 years, then annually. Additionally, every 4 weeks during adjuvant durvalumab. Maximum follow-up at time of analysis was 4.2 years. | |
Secondary | Competing Mortality (Percentage of Participants Who Died Due to Causes Other Than Study Cancer) | Failure is defined as Death from second primary, protocol treatment, or "other cause". Failure time is defined as time from randomization to first occurrence of failure, death due to study cancer or unknown cause (competing risk), or last follow-up (censored). Failure rates are estimated using the cumulative incidence method. The protocol specifies that the distributions of failure times be compared between the arms, which is reported in the statistical analysis results. Two-year estimates are provided. | From randomization to last follow-up: weekly during RT, after end of RT: every 4 months for 1 year, every 6 months for 2 years, then annually. Additionally, every 4 weeks during adjuvant durvalumab. Maximum follow-up at time of analysis was 4.2 years. | |
Secondary | Percentage of Participants With Complete or Partial Response at 4-month Scan Determined by Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1 | Fludeoxyglucose F-18 positron emission tomography/computed tomography (FDG-PET/CT) scans at baseline and four months after the end of radiation therapy are compared.
Per RECIST 1.1: Complete response: Disappearance of all lesions and pathologic lymph nodes Partial response: = 30% decrease sum of the longest diameters No new lesions No progression of non-target lesions |
Baseline and 4 months after end of RT (approximately 6.5 months) | |
Secondary | Number of Participants by Highest Grade Adverse Event Reported | Common Terminology Criteria for Adverse Events (version 5.0) grades adverse event severity from 1=mild to 5=death. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data. | From randomization to last follow-up: weekly during RT, RT end, from end of RT: months 1, (Cetuximab: 2, 3,) 4, 8, 12, 18, 24, 30, 36, then annually. Additionally, prior to each adjuvant durvalumab cycle. Maximum follow-up at time of analysis= 4.2 yr. | |
Secondary | Change in Quality of Life (QOL) Analysis | Assessed using European Organization for Research and Treatment of Cancer Core Questionnaire (EORTC QLQ)/Head-and-Neck module (H&N35), EuroQol- 5 Dimension (EQ5D), M. D. Anderson Dysphagia Inventory (MDADI), patient reported outcomes (PRO)-CTCAE, geriatric screening (G8). The mean summary score of the EORTC QLQ/H&N35, EQ5D, MDADI, PRO-CTCAE, G8, CCI, and the subscales will be determined. The mean change from baseline at each time point will be summarized using mean and standard deviations for each arm. Mean change from baseline will be compared between the arms using a two sample t test. If data normality assumptions are not met, the Wilcoxon rank sum test will be used to test the hypothesis. Mean change from baseline will be tested using an omnibus F test followed by individual comparisons of change scores at different time points within each treatment group. The same analysis will be conducted for between group comparisons at each time point. | Baseline up to 12 months | |
Secondary | Change in Swallowing QOL Using Total Composite M. D. Anderson Dysphagia Inventory (MDADI) Score | The mean change from baseline at each time point will be summarized using mean and standard deviations for each arm. Mean change from baseline will be compared between the arms using a two sample t test. If data normality assumptions are not met, the Wilcoxon rank sum test will be used to test the hypothesis. | Baseline up to 1 year | |
Secondary | Translational Research, Including PD-L1 and p16 | Analyses of interaction between treatment arm and marker status will be done. Additionally toxicity for the two arms by marker status will be compared. Univariable and multivariable analysis will be performed using the Cox proportional hazards model for overall survival. Potential covariates evaluated for the multivariate models would be assigned treatment, age, Zubrod performance status, T-stage, N-stage, primary site, smoking history, other risk factors, as well as p16 and/PD-L1. | Up to 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Recruiting |
NCT03317327 -
REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT02892201 -
Pembrolizumab in HNSCC With Residual Disease After Radiation
|
Phase 2 | |
Active, not recruiting |
NCT04854499 -
Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Terminated |
NCT04110249 -
Photoacoustic Imaging for Measuring Tumors and Normal Tissue in Patients With Head and Neck Cancer
|
N/A | |
Terminated |
NCT02495896 -
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT05338905 -
Intensive Symptom Surveillance Guided by Machine Learning-Directed Risk Stratification in Patients With Non-Metastatic Head and Neck Cancer, The INSIGHT Trial
|
N/A | |
Recruiting |
NCT04045496 -
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04452214 -
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04096638 -
Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03070366 -
Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC
|
Phase 2 | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Recruiting |
NCT02661152 -
DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC.
|
Phase 3 | |
Terminated |
NCT02488629 -
Study of SCB01A in Patient With Head and Neck Cancer
|
Phase 2 | |
Completed |
NCT01697800 -
A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract
|
Phase 2 | |
Completed |
NCT01427478 -
Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck
|
Phase 3 | |
Recruiting |
NCT05437380 -
Peritumoral Microbubbles and CEUS for SLN Detection and Biopsy in HNSCC
|
N/A | |
Recruiting |
NCT05065086 -
Single Modality Trans Oral Robotic Surgery for Primary Oropharyngeal Cancer: Exploring the Impact of Surgical Margins on Local Disease Recurrence
|
||
Completed |
NCT03022409 -
A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).
|
Phase 1 |